Bedrijfsoverzicht
BioCryst Pharmaceuticals, Inc. is a biotechnology firm dedicated to the development and commercialization of therapeutic medicines targeting hereditary angioedema (HAE) and other rare diseases, alongside the marketing of peramivir injection for influenza treatment. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche therapeutic areas with specialized regulatory pathways and manufacturing requirements. The firm employs a workforce of 435 individuals and holds a market capitalization of $2.40B, generating annual revenue of $874.84M. These financial figures indicate that BioCryst maintains a significant operational scale within the specialty pharmaceutical landscape, positioning it as a substantial player capable of sustaining R&D expenditures and commercialization efforts for orphan drugs. The substantial market cap relative to its revenue suggests the market values the company's intellectual property portfolio and its specific niche in rare disease therapeutics highly, reflecting confidence in its pipeline potential despite the inherent risks associated with biotechnology development.
Financiële gezondheid
BioCryst reported a revenue of $874.84M and net income of $263.86M over the trailing twelve months, while its EBITDA stands at $350.79M. The significant gap between revenue and net income reveals a highly efficient cost structure where the company retains approximately 30.2% of every dollar earned as profit, indicating robust operational leverage. The firm generated free cash flow of $256.42M, which provides a strong foundation for financial flexibility, allowing for continued investment in research and development or strategic acquisitions without immediate reliance on external capital markets. Profitability is further underscored by a gross margin of 79.1%, an operating margin of 65.6%, and a profit margin of 30.2%, each demonstrating exceptional efficiency in converting sales into earnings at various stages of the production and operational lifecycle. Regarding liquidity and solvency, the company holds $274.75M in cash against $477.33M in debt, while the debt-to-equity ratio is listed as N/A, suggesting a balance sheet structure that prioritizes asset backing over traditional equity leverage metrics. The current ratio of 2.06 indicates that the company possesses more than double the current assets required to cover its short-term liabilities, reflecting a conservative approach to working capital management. Furthermore, the return on equity is N/A and the return on assets stands at 43.2%, the latter metric revealing that management generates a high return on the total asset base, which is particularly notable given the capital-intensive nature of biopharmaceutical operations.
Waarderingsbeoordeling
The stock carries a P/E ratio (TTM) of 7.90 and a forward P/E of 11.92, where the difference between these two figures implies that the market expects earnings growth to accelerate in the coming year, thereby justifying a higher multiple on future earnings. The price to book ratio is -17.10, a negative figure that typically indicates the market values the company's intangible assets, such as its drug pipeline, significantly above its recorded book value, or reflects accounting adjustments common in biotechnology firms. Alternative valuation metrics show a price to sales ratio of 2.74 and an EV/EBITDA of 7.41, suggesting that the market prices the company at a premium relative to its sales and earnings before interest, taxes, depreciation, and amortization, consistent with high-margin specialty drug manufacturers. The stock has traded between a 52-week low of $6.00 and a 52-week high of $11.31, and the current trading position relative to this range must be calculated based on the available data points, though the specific current price is not explicitly stated in the provided facts, the beta of 0.69 indicates that the stock exhibits lower volatility than the broader market, moving less than 69% as much as the market index. This lower beta suggests that the stock may provide a stabilizing element to a portfolio during periods of heightened market turbulence, as it does not amplify market swings to the same degree as large-cap equities.
Growth & Income
Revenue growth for the company is reported at an impressive 209.1% year-over-year, while earnings growth is listed as N/A, indicating that the substantial increase in sales has outpaced the current earnings trajectory, likely due to the non-recurring nature of certain costs or the specific timing of revenue recognition for blockbuster drugs. For non-dividend payers, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, which explains that the firm reinvests all its earnings back into the business rather than distributing cash to shareholders, a strategy common in biotechnology to fund pipeline development. The overall growth and income profile is characterized by explosive sales expansion that has not yet fully translated into proportional earnings growth, combined with a capital allocation strategy that prioritizes internal growth and asset accumulation over shareholder payouts. This dynamic creates a unique investment thesis where value is derived from sales velocity and pipeline potential rather than current dividend income.